ADVERTISEMENT
References
- Loo E, Khalili P, Beuhler K, et al. BRAF V600E Mutation Across Multiple Tumor Types: Correlation Between DNA-based Sequencing and Mutation-specific Immunohistochemistry. Appl Immunohistochem Mol Morphol. 2018;26(10):709-713.
- Davies H, Bigneli G, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417:949-54.
- Croce L, Coperchini F, Magri F, et al. The multifaceted anti-cancer effects of BRAF-inhibitors. Oncotarget. 2019;10(61):6623-6640.
- Korphaisarn K, Kopetz S. BRAF-Directed Therapy in Metastatic Colorectal Cancer. Cancer J. 2016;22(3):175-178.
- Ducreux M, Chamseddine A, Laurent-Puig P, et al. Molecular targeted therapy of BRAF-mutant colorectal cancer. Ther Adv Med Oncol. 2019;11:1758835919856494.
- Tiacci E, Trifonov V, Schiavoni G, et al. BRAF mutations in hairy-cell leukemia. N Engl J Med. 2011; 364:2305-2315.
- Alvarez JGB, Otterson GA. Agents to treat BRAF-mutant lung cancer. Drugs Context. 2019;8:212566.
- Ascierto PA, Kirkwood JM, Grob JJ, et al. The role of BRAF V600 mutation in melanoma. J Transl Med. 2012;10:85.
- Danu A, Cotteret S, Lacroix L, et al. BRAF V600E targetable mutation in relapsed/refractory multiple myeloma (R/R MM) patients: A high incidence in R/R MM detected using cell sorting screening. Blood. 2016;128(22):5638.
- Moulana FI, Priyani AAH, de Silva MVC, et al. BRAF-oncogene-induced senescence and the role of thyroid-stimulating hormone signaling in the progression of papillary thyroid carcinoma. Horm Canc. 2018;9:1-11.
- Kebebew E, Weng J, Bauer J, et al. The prevalence and prognostic value of BRAF mutation in thyroid cancer. Ann Surg. 2007;246(3):466-471.
